CR20120493A - Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis - Google Patents
Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosisInfo
- Publication number
- CR20120493A CR20120493A CR20120493A CR20120493A CR20120493A CR 20120493 A CR20120493 A CR 20120493A CR 20120493 A CR20120493 A CR 20120493A CR 20120493 A CR20120493 A CR 20120493A CR 20120493 A CR20120493 A CR 20120493A
- Authority
- CR
- Costa Rica
- Prior art keywords
- endometriosis
- treatment
- aromatase
- gestagens
- inhibitors
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title abstract 2
- 102000014654 Aromatase Human genes 0.000 title 1
- 108010078554 Aromatase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000583 progesterone congener Substances 0.000 title 1
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 2
- 239000003886 aromatase inhibitor Substances 0.000 abstract 2
- 230000000638 stimulation Effects 0.000 abstract 2
- 102000006771 Gonadotropins Human genes 0.000 abstract 1
- 108010086677 Gonadotropins Proteins 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 230000003325 follicular Effects 0.000 abstract 1
- 239000002622 gonadotropin Substances 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 239000006201 parenteral dosage form Substances 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
El contenido de la presente invención para el tratamiento de endometriosis consiste en proporcionar una forma farmacéutica parenteral (sistema de administración) para la liberación controlada de un inhibidor de aromatasa (AI) con una tasa de liberación diaria, que no induce una estimulación de los ovarios por reacoplamiento negativo del eje hipófisis-ovario (que provocaría una secreción de gonadotropinas y estimulación del crecimiento folicular ovárico),
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010003494A DE102010003494A1 (de) | 2010-03-31 | 2010-03-31 | Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20120493A true CR20120493A (es) | 2012-11-22 |
Family
ID=44021822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20120493A CR20120493A (es) | 2010-03-31 | 2012-09-27 | Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis |
Country Status (41)
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CN107850568A (zh) * | 2015-05-27 | 2018-03-27 | 奎斯特诊断投资有限公司 | 用于质谱定量由微量取样装置提取的分析物的方法 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
UA124382C2 (uk) * | 2015-12-21 | 2021-09-08 | Баєр Ой | Спосіб виготовлення пристрою для доставки лікарського засобу |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
GB201614179D0 (en) * | 2016-08-19 | 2016-10-05 | Mereo Biopharma 2 Ltd | Dosage regimen for the treatment of endometriosis |
CN109248166A (zh) * | 2017-07-13 | 2019-01-22 | 国家卫生计生委科学技术研究所 | 阿那曲唑储库型阴道环的制备及应用 |
US10918649B2 (en) | 2019-06-21 | 2021-02-16 | The Population Council, Inc. | System for providing birth control |
WO2022174074A1 (en) * | 2021-02-12 | 2022-08-18 | The Regents Of The University Of California | Endometriosis-related methods and compositions |
CN115804762A (zh) * | 2022-12-20 | 2023-03-17 | 浙江大学 | 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8517360D0 (en) * | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
JP2602456B2 (ja) * | 1990-04-12 | 1997-04-23 | 雪印乳業株式会社 | 子宮内膜症治療剤 |
FI95768C (fi) * | 1993-06-17 | 1996-03-25 | Leiras Oy | Emättimensisäinen antosysteemi |
US7744916B2 (en) * | 1997-06-11 | 2010-06-29 | Umd, Inc. | Coated vaginal device for delivery of anti-migraine and anti-nausea drugs |
FI20000572A (fi) * | 2000-03-13 | 2001-09-14 | Leiras Oy | Implantaattien asettamiseen tarkoitettu laite |
MXPA03006607A (es) * | 2001-01-26 | 2003-09-22 | Upjohn Co | Metodo combinado para tratar trastornos dependientes de hormonas. |
GB0120147D0 (en) * | 2001-08-17 | 2001-10-10 | Metris Therapeutics Ltd | Treatment method |
WO2003017974A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method |
GB0302572D0 (en) * | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
GB0320238D0 (en) * | 2003-08-29 | 2003-10-01 | Medical Res Council | Treatment of disease |
US20050101579A1 (en) * | 2003-11-06 | 2005-05-12 | Shippen Eugene R. | Endometriosis treatment protocol |
US8741329B2 (en) * | 2007-09-21 | 2014-06-03 | Merck Sharp & Dohme B.V. | Drug delivery system |
TW200927141A (en) * | 2007-11-22 | 2009-07-01 | Bayer Schering Pharma Oy | Vaginal delivery system |
US20110033519A1 (en) * | 2009-08-07 | 2011-02-10 | Leong Madeline | Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use |
-
2010
- 2010-03-31 DE DE102010003494A patent/DE102010003494A1/de not_active Withdrawn
-
2011
- 2011-03-28 CN CN201180017806.6A patent/CN103002873B/zh not_active Expired - Fee Related
- 2011-03-28 BR BR112012024739A patent/BR112012024739A2/pt not_active IP Right Cessation
- 2011-03-28 MX MX2012011329A patent/MX2012011329A/es active IP Right Grant
- 2011-03-28 CA CA2794790A patent/CA2794790A1/en not_active Abandoned
- 2011-03-28 EP EP11714245.5A patent/EP2552404B1/de active Active
- 2011-03-28 PE PE2012001815A patent/PE20130524A1/es not_active Application Discontinuation
- 2011-03-28 MA MA35266A patent/MA34099B1/fr unknown
- 2011-03-28 PL PL11714245T patent/PL2552404T3/pl unknown
- 2011-03-28 AU AU2011234587A patent/AU2011234587B2/en not_active Ceased
- 2011-03-28 SG SG2012068847A patent/SG184111A1/en unknown
- 2011-03-28 ES ES11714245.5T patent/ES2533101T3/es active Active
- 2011-03-28 UA UAA201212231A patent/UA109655C2/uk unknown
- 2011-03-28 DK DK11714245.5T patent/DK2552404T3/en active
- 2011-03-28 ME MEP-2015-39A patent/ME02159B/me unknown
- 2011-03-28 NZ NZ602698A patent/NZ602698A/en not_active IP Right Cessation
- 2011-03-28 JP JP2013501792A patent/JP6012048B2/ja not_active Expired - Fee Related
- 2011-03-28 US US13/638,243 patent/US20130131027A1/en not_active Abandoned
- 2011-03-28 PT PT11714245T patent/PT2552404E/pt unknown
- 2011-03-28 EA EA201201358A patent/EA025582B1/ru not_active IP Right Cessation
- 2011-03-28 SI SI201130435T patent/SI2552404T1/sl unknown
- 2011-03-28 WO PCT/EP2011/054737 patent/WO2011120925A1/de active Application Filing
- 2011-03-28 RS RS20150188A patent/RS53876B1/en unknown
- 2011-03-28 KR KR1020127025671A patent/KR20130010047A/ko not_active Application Discontinuation
- 2011-03-28 MY MYPI2012004360A patent/MY160353A/en unknown
- 2011-03-30 TW TW105118443A patent/TW201632184A/zh unknown
- 2011-03-30 TW TW100111100A patent/TWI576107B/zh not_active IP Right Cessation
- 2011-03-30 UY UY0001033303A patent/UY33303A/es not_active Application Discontinuation
- 2011-03-30 AR ARP110101037A patent/AR080861A1/es unknown
-
2012
- 2012-09-13 ZA ZA2012/06869A patent/ZA201206869B/en unknown
- 2012-09-23 IL IL222056A patent/IL222056A/en not_active IP Right Cessation
- 2012-09-24 EC ECSP12012176 patent/ECSP12012176A/es unknown
- 2012-09-27 CR CR20120493A patent/CR20120493A/es unknown
- 2012-09-27 TN TNP2012000468A patent/TN2012000468A1/en unknown
- 2012-09-28 GT GT201200267A patent/GT201200267A/es unknown
- 2012-09-28 CU CU2012000145A patent/CU20120145A7/es unknown
- 2012-09-28 CL CL2012002722A patent/CL2012002722A1/es unknown
- 2012-09-28 CO CO12170798A patent/CO6630125A2/es unknown
- 2012-09-28 DO DO2012000255A patent/DOP2012000255A/es unknown
-
2013
- 2013-06-13 HK HK13106968.0A patent/HK1179531A1/xx not_active IP Right Cessation
-
2015
- 2015-03-16 HR HRP20150294TT patent/HRP20150294T1/hr unknown
- 2015-03-17 CY CY20151100269T patent/CY1116187T1/el unknown
- 2015-06-18 US US14/743,935 patent/US20150359802A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115248A patent/JP2016164200A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20120493A (es) | Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis | |
AR117670A2 (es) | Modulador del receptor de andrógeno y sus usos | |
AR127861A2 (es) | Composición farmacéutica que comprende inhibidores del proteasoma peptídico y ciclodextrina | |
CO7240407A2 (es) | Formas cristalinas de un modulador del receptor androgénico | |
IN2014DN06529A (es) | ||
UY34132A (es) | Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab. | |
PE20142239A1 (es) | Sistemas intrauterinos, dispositivos de insercion diu, y metodos relacionados y kits de los mismos | |
AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
BR112013004440A2 (pt) | método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral | |
AR077225A1 (es) | Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza | |
EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
PE20150190A1 (es) | Formulacion farmaceutica | |
UY34178A (es) | Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológicos. | |
CL2016001094A1 (es) | Silicato de zirconio microporoso para el tratamiento de hipercalemia. | |
MX337464B (es) | Profarmacos lipofilicos labiles al acido de los agentes quimioterapeuticos contra el cancer. | |
AR100365A1 (es) | Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla | |
EA201490862A1 (ru) | Осмотически активная система вагинальной доставки | |
AR091886A1 (es) | Dispositivo dispensador | |
UY34154A (es) | Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel. | |
AR095834A1 (es) | Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica | |
UY35004A (es) | Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen | |
UA116104C2 (uk) | Інгібітор сигнального шляху рецептора cd95 для застосування в лікуванні мієлодиспластичного синдрому | |
AR125339A2 (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
EA201592232A1 (ru) | Применение денцихина в получении лекарственного средства для лечения тромбоцитопении |